Routine Spironolactone in Acute Myocardial Infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Mineralocorticoid receptor antagonists (MRAs) are established treatments for reducing mortality in patients with heart failure post-myocardial infarction (MI).
• The routine use of spironolactone, an MRA, in the broader post-MI population without established heart failure remains uncertain.

Purpose of the Study:

• To investigate the efficacy of spironolactone in reducing cardiovascular mortality and heart failure events in patients following myocardial infarction.
• To assess the impact of spironolactone on a composite of major adverse cardiovascular events, including MI, stroke, heart failure, and cardiovascular death.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled trial with a 2x2 factorial design was conducted.
• 7062 patients post-MI who underwent percutaneous coronary intervention were randomized to receive either spironolactone or placebo.
• Primary outcomes included a composite of cardiovascular death or new/worsening heart failure, and a composite of first occurrence of MI, stroke, new/worsening heart failure, or cardiovascular death.

Main Results:

• Spironolactone did not significantly reduce the first primary outcome (cardiovascular death or new/worsening heart failure) compared to placebo (HR 0.91, P=0.51).
• The second primary outcome (composite of cardiovascular death, MI, stroke, or new/worsening heart failure) was also not significantly reduced by spironolactone (HR 0.96, P=0.60).
• Serious adverse events were comparable between the spironolactone and placebo groups.

Conclusions:

• Routine use of spironolactone in patients after myocardial infarction did not lead to a significant reduction in cardiovascular death, heart failure, or other major adverse cardiovascular events.
• The findings suggest that spironolactone may not offer additional benefits in this specific patient population beyond established therapies.